The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | The current standard of care for patients with lower-risk MDS
Shuh Ying Tan, MBBS, BMedSci, FRACP, FRCPA, St Vincent’s Hospital Melbourne, Melbourne, Australia, briefly discusses the current standard of care for patients with lower-risk myelodysplastic syndromes (MDS), drawing focus on the importance of supportive care, reducing cytopenia, and improving quality of life. Dr Tan also mentions promising novel agents in the field. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
